Immunic Inc.

AI Score

XX

Unlock

1.12
0.06 (5.16%)
At close: Apr 02, 2025, 3:59 PM
1.07
-4.46%
After-hours: Apr 02, 2025, 07:04 PM EDT
5.16%
Bid 1.02
Market Cap 100.89M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -1.23
PE Ratio (ttm) -0.91
Forward PE -1.29
Analyst Buy
Ask 1.15
Volume 697,781
Avg. Volume (20D) 851,213
Open 1.05
Previous Close 1.06
Day's Range 1.05 - 1.15
52-Week Range 0.92 - 2.11
Beta 1.90

About IMUX

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company i...

Industry Biotechnology
Sector Healthcare
IPO Date Apr 17, 2014
Employees 85
Stock Exchange NASDAQ
Ticker Symbol IMUX
Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for IMUX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 792.86% from the latest price.

Stock Forecasts
1 month ago
+12.38%
Immunic shares are trading higher after the compan... Unlock content with Pro Subscription
4 months ago
+7.27%
Immunic shares are trading higher after HC Wainwright initiated coverage on the stock with a Buy rating and announced a $10 price target.